Ashvattha Therapeutics

Ashvattha Therapeutics originated from scientific experts in nanomedicine and entrepreneurs with a history of establishing numerous businesses. The company's leadership team has acquired over $1 billion in funding through IPOs and has progressed therapeutic products from IND to commercial release. Together, they are working on developing dendrimer drug conjugates spanning various therapeutic areas. Additionally, they are pursuing partnerships with biopharmaceutical companies to facilitate the precise delivery of their therapeutics.